Fuente y mas informacion:
jueves, 5 febrero, 2009
De: "MMRF SmartBrief "
http://www.multiplemyeloma.org/

Br J Haematol. 2009 Jan 12
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J


Br J Haematol. 2009 Jan 16
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blad? J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J


Blood. 2009 Jan 26
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Inhibition of Aurora-kinases for tailored risk adapted treatment of multiple myeloma
Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Kramer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Mohler T, Blake J, Zimmermann J, Klein B, Goldschmidt H


Blood. 2009 Jan 29
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, Phelps TK, Dispenzieri A, Kumar SK, Katzmann JA, Rajkumar SV


Blood. 2009 Jan 29
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma: a prospective study
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV


Blood. 2009 Jan 30
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Lenalidomide (Revlimid(R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC[list=1]





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:
Myeloma Minute - February 6, 2009
http://readtheminute.myeloma.org/

Lenalidomide (Revlimid(R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
http://bloodjournal.hematologylibra...84135v1?papetoc
Blood published 30 January 2009, 10.1182/blood-2008-10-184135

Videos from ASH 2008 on the Web
http://myeloma.org/main.jsp?source=...enu_id=0&id=175
They report significant progress in all aspects of myeloma research—genetic studies, high-risk myeloma, new agents and more.

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
http://www.mayoclinicproceedings.com/content/84/2/114.full
Mayo Clinic Proceedings February 2009 vol. 84 no. 2 114-122





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:
jueves, 19 febrero, 2009
De: "MMRF SmartBrief "
http://www.multiplemyeloma.org/

Biol Blood Marrow Transplant. 2008 Jan
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Multiple myeloma: biology, standard therapy, and transplant therapy
Gertz MA, Ghobrial I, Luc-Harousseau J


Leuk Lymphoma. 2009 Feb 4:1-7
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Predicting durable remissions following thalidomide therapy for relapsed myeloma
Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Miles Prince H


Blood. 2009 Feb 3
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, Petasis NA, Chen TC, Schonthal AH


Blood. 2009 Feb 4
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling
Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr.


Blood. 2009 Feb 4
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC


Clin Cancer Res. 2009 Feb 1
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma
Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.